ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression

Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) have been approved for both frontline and recurrent setting in ovarian cancer with homologous recombination (HR) repair deficiency. However, more than 40% of BRCA1/2-mutated ovarian cancer lack the initial response to PARPi treatment, and the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavudi, Kousalya, Banerjee, Ananya, Li, Na, Yang, Yajing, Cai, Shurui, Bai, Xuetao, Zhang, Xiaoli, Li, Aidan, Wani, Elsa, Yang, Shyh-Ming, Zhang, Junran, Rai, Ganesha, Backes, Floor, Patnaik, Srinivas, Guo, Peixuan, Wang, Qi-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333219/
https://www.ncbi.nlm.nih.gov/pubmed/37429899
http://dx.doi.org/10.1038/s41698-023-00411-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333219/
https://www.ncbi.nlm.nih.gov/pubmed/37429899
http://dx.doi.org/10.1038/s41698-023-00411-x

Ejemplares similares